Contribute Try STAT+ Today

SAN FRANCISCO — About two years ago, Simon Smith started counting the startups trying to bring artificial intelligence to drug development. Smith, an AI startup executive himself, found about 30 of them. Now? His tally is up to 148.

Smith’s list is incomplete — some companies are still in stealth mode, and others are hard to classify because they straddle the line between AI and traditional biotech — but its rapid growth is a clear sign of an industry on the rise. With big checks from venture capitalists and exploratory deals with drug makers, these startups are trying to cut costs and speed up progress in everything from discovering therapeutic targets to enrolling patients in clinical trials.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.